Ataergin Selmin, Arpaci Fikret, Cetin Turker, Guran Sefik, Yakicier Cengiz, Beyzadeoglu Murat, Ozet Ahmet
Department of Medical Oncology and Bone Marrow Transplantation Unit, Gulhane Faculty of Medicine, Ankara, Turkey.
Am J Hematol. 2006 May;81(5):370-3. doi: 10.1002/ajh.20615.
A 38-year-old female with chronic myeloid leukemia underwent an allogeneic bone marrow transplantation from her full-matched brother. Eleven months later, she readmitted with an acute leukemia that was shown to be of donor origin. The patient never achieved a remission even after chemotherapies with cytarabine and mitoxantrone, donor lymphocyte infusion, and second allogeneic peripheral blood stem cell transplantation. Donor cell leukemia (DCL) is sometimes misdiagnosed as relapse by clinicians and the real incidence may be higher than expected. Cytogenetic and molecular techniques may be helpful to clarify the issue of the leukemia. The current case is another case of DCL reported in the literature after an allogeneic transplant for a kind of leukemia.
一名38岁的慢性髓性白血病女性接受了来自其全相合兄弟的异基因骨髓移植。11个月后，她因急性白血病再次入院，结果显示该急性白血病源自供体。即便接受了阿糖胞苷和米托蒽醌化疗、供体淋巴细胞输注以及第二次异基因外周血干细胞移植，该患者仍未实现缓解。供体细胞白血病（DCL）有时会被临床医生误诊为复发，其实际发病率可能高于预期。细胞遗传学和分子技术可能有助于厘清白血病问题。本病例是文献中报道的异基因移植治疗一种白血病后发生DCL的又一病例。
